Core Viewpoint - Quantum BioPharma Ltd. is conducting a non-brokered private placement of up to 30 Class A Multiple Voting Shares at a price of $25 per share, aiming for gross proceeds of up to $750 million, primarily to enhance voting rights and for general working capital purposes [1][2]. Group 1: Offering Details - The private placement is expected to be fully subscribed by entities controlled by Zeeshan Saeed and Anthony Durkacz, existing holders of Class A Multiple Voting Shares [1][3]. - If fully subscribed, the voting rights attached to Class A Multiple Voting Shares will increase to 75.27%, nearly restoring the percentage to that at the time of the company's IPO in 2018 [2]. - The board of directors unanimously approved the Offering, excluding Saeed and Durkacz from discussions due to their interests [2]. Group 2: Related Party Transactions - The Offering involves related-party transactions as it is anticipated that Xorax Family Trust and Fortius Research and Trading Corp. will purchase all Class A Multiple Voting Shares issued [3]. - The transaction is expected to be exempt from formal valuation and minority shareholder approval requirements under MI 61-101, as the fair market value will not exceed 25% of the company's market capitalization [3]. Group 3: Shareholder Structure - Prior to a recent transfer, the Transferor and Joint Actors held approximately 50% of the outstanding Class A Multiple Voting Shares and 24.85% of the voting rights attached to all voting securities [7]. - Following the transfer of 77,000 Class B Subordinate Voting Shares, the ownership structure changed, with the Transferor and Joint Actors now holding approximately 23.77% of the voting rights [8]. Group 4: Company Overview - Quantum BioPharma focuses on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, with its lead compound, Lucid-MS, aimed at treating multiple sclerosis [12]. - The company retains a 20.10% ownership in Unbuzzd Wellness Inc., which includes a royalty agreement for sales from its product unbuzzd™ [12].

Core Viewpoint - Quantum BioPharma Ltd. announces a $5 million Reg D 506(c) offering through its licensee Unbuzzd Wellness Inc., which has developed a beverage that accelerates alcohol metabolism and reduces hangover symptoms, with no dilution for Quantum BioPharma shareholders [1][4]. Company Overview - Quantum BioPharma is focused on innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, with drug candidates at various development stages [1][8]. - The company retains a 20.10% ownership stake in Unbuzzd Wellness Inc. and is entitled to a 7% royalty on sales until reaching $250 million, after which the royalty will decrease to 3% [8]. Unbuzzd Wellness Inc. Details - Unbuzzd Wellness Inc. is a public issuer specializing in wellness and recovery supplements, with a product designed to enhance alcohol metabolism and cognitive function [5][8]. - The beverage, unbuzzd, is backed by clinical research and aims to meet consumer needs for responsible drinking [3][5]. Clinical Trial Findings - A clinical trial demonstrated that unbuzzd accelerates alcohol metabolism, reducing blood alcohol concentration (BAC) by over 40% faster within 30 minutes compared to control subjects [6][12]. - Participants reported significant improvements in alertness and cognitive performance shortly after consuming unbuzzd, with no adverse side effects noted [6][12]. Investor Webinar - An investor webinar is scheduled for October 30, 2025, where Unbuzzd leadership will discuss the investment opportunity and plans for scaling distribution [2][3]. - The offering is targeted at accredited investors, aiming to expand direct-to-consumer and retail availability, with potential plans for an IPO [3].

Core Viewpoint - Quantum BioPharma Ltd. strongly refutes allegations of securities law violations made by The Schall Law Firm and DJS Law Group, describing the claims as vague and unsubstantiated [1][2]. Company Overview - Quantum BioPharma is a biopharmaceutical company focused on developing innovative treatments for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [5]. - The company is advancing its lead compound, Lucid-MS, which is designed to prevent and reverse myelin degradation associated with multiple sclerosis [5]. - Quantum BioPharma retains a 20.10% ownership stake in Unbuzzd Wellness Inc., which is linked to its product unbuzzd™, and has a royalty agreement that includes 7% of sales until reaching $250 million, after which the royalty will drop to 3% [5]. Legal Response - The company views the announcements from the law firms as opportunistic litigation tactics aimed at exploiting public markets without merit [3]. - Quantum BioPharma is reviewing the conduct of the law firms involved and plans to take appropriate action to protect its reputation [3]. Call for Information - The company invites individuals or entities who feel they have been treated unfairly by the law firms to come forward, assuring confidentiality [4].

Core Points - Quantum BioPharma Ltd. has announced a public whistleblower policy offering rewards up to USD $7 million for information leading to a trial victory or settlement in its ongoing lawsuit against major financial institutions for stock manipulation [1][3][9] - The lawsuit seeks over USD $700 million in damages due to alleged illegal tactics, including "spoofing," which artificially depressed the company's stock price from approximately USD $460 in early 2020 to less than USD $10 by late 2024 [10][9] - The company emphasizes its commitment to restoring market integrity and holding alleged perpetrators accountable through this initiative [5][12] Whistleblower Policy - The cash reward will be granted if the information significantly contributes to a final judgment or binding settlement [3][4] - Eligible information includes evidence of illegal trading practices, such as spoofing and spreading false information [3][4] - The program does not interfere with existing SEC whistleblower programs, allowing individuals to report directly to the SEC while also participating in Quantum's initiative [6][7] Legal Context - The lawsuit is characterized as one of the largest spoofing cases in decades, with substantial evidence gathered by experienced law firms [10][12] - The company is actively seeking additional evidence and information from individuals who may have knowledge of the alleged manipulation [13][11] - Legal representation is provided on a contingency basis, meaning the company incurs no upfront legal costs [10] Company Overview - Quantum BioPharma focuses on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders [14] - The company retains a 20.10% ownership stake in Unbuzzd Wellness Inc., with a royalty agreement that could yield significant future revenues [14] - The company is committed to involving its shareholder community in addressing the impacts of stock manipulation [13]

Core Viewpoint - Quantum BioPharma Ltd. has announced the establishment of October 27, 2025, as the record date for the distribution of contingent value rights (CVRs) to holders of its Class B Subordinate Voting Shares, linking potential future recoveries from ongoing litigation directly to shareholders [1][3]. Group 1: CVR Distribution Details - Each CVR will allow holders to receive a pro rata portion of a minimum of 10% and up to 50% of the net proceeds recovered from the Company's legal action against CIBC World Markets, RBC Dominion Securities, and others, which alleges stock price manipulation and seeks damages exceeding USD $700 million [2]. - Payments under the CVRs will only occur if the Company receives net proceeds from the litigation following a settlement or a final, non-appealable judgment, referred to as "Qualifying Net Proceeds" [2][4]. - The distribution date for the CVRs is currently undetermined and contingent upon the Company receiving Qualifying Net Proceeds from the litigation [5]. Group 2: Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, with its lead compound, Lucid-MS, aimed at preventing and reversing myelin degradation associated with multiple sclerosis [6]. - The Company retains a 20.10% ownership stake in Unbuzzd Wellness Inc., which is involved in the development of the unbuzzd™ product, and is entitled to royalty payments of 7% of sales until total payments reach $250 million, after which the royalty rate will drop to 3% [6]. - Quantum BioPharma also maintains a portfolio of strategic investments through its subsidiary, FSD Strategic Investments Inc., which includes loans secured by residential or commercial property [6].

Core Viewpoint - Quantum BioPharma Ltd. announces a $5 million fundraising initiative through its licensee Unbuzzd Wellness Inc., which offers a scientifically-backed beverage aimed at enhancing alcohol metabolism and reducing hangover symptoms, without diluting existing shareholders [1][3]. Company Overview - Quantum BioPharma is a biopharmaceutical company focused on developing innovative treatments for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [1][7]. - Unbuzzd Wellness Inc. is a public issuer that specializes in wellness and recovery supplements, particularly a beverage designed to aid in alcohol metabolism and cognitive recovery [4][7]. Product Details - Unbuzzd is a beverage that accelerates alcohol metabolism, restores mental clarity, and alleviates hangover symptoms, developed by a team of experts in pharmacology and medicine [4][5]. - The product has undergone a clinical trial demonstrating significant efficacy, including a more than 40% faster reduction in blood alcohol concentration (BAC) within 30 minutes compared to control subjects [5]. Clinical Trial Findings - Key findings from the clinical trial include: - Accelerated alcohol metabolism with a significant reduction in BAC [5]. - Statistically significant improvements in alertness and cognitive performance within 30 minutes of consumption [5]. - Stabilization of heart rate and blood pressure during alcohol intoxication [5]. - Notable reduction in hangover symptoms, including a 67% reduction in headache severity at four hours post-consumption [5][6]. - Unbuzzd was well-tolerated with no reported adverse side effects [6]. Investment Opportunity - Unbuzzd is hosting an investor webinar to discuss the investment opportunity related to its beverage and plans for scaling distribution and retail sales [2][3]. - The company aims to raise up to $5 million to support its expansion plans and potentially pave the way for an initial public offering [3]. Ownership and Financial Structure - Quantum BioPharma retains a 20.10% ownership stake in Unbuzzd Wellness Inc. and is entitled to a 7% royalty on sales until reaching $250 million, after which the royalty will decrease to 3% [7].

Core Viewpoint - Quantum BioPharma Ltd. announced that its licensee, Unbuzzd Wellness Inc., will host an Investor Webinar to discuss their innovative beverage designed to accelerate alcohol metabolism and reduce hangover symptoms, highlighting a significant investment opportunity [1][2][3]. Company Overview - Quantum BioPharma is a biopharmaceutical company focused on developing innovative solutions for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders [1][7]. - The company retains a 20.10% ownership stake in Unbuzzd Wellness Inc. and is entitled to a 7% royalty on sales from the unbuzzd beverage until total payments reach $250 million, after which the royalty will decrease to 3% [7]. Product Details - Unbuzzd is a scientifically-proven beverage that accelerates alcohol metabolism, restores mental clarity, and alleviates hangover symptoms [1][5]. - The product is backed by a double-blind, placebo-controlled clinical trial demonstrating that unbuzzd reduces blood alcohol concentration (BAC) by over 40% faster within 30 minutes compared to control subjects [5]. - Participants reported significant improvements in alertness and reductions in perceived impairment and hangover symptoms, including a 67% reduction in headache severity at four hours post-consumption [5][6]. Investment Opportunity - Unbuzzd Wellness Inc. is currently offering a Regulation D 506(c) investment opportunity, aiming to raise up to $5 million to support its expansion plans and potential initial public offering [3]. - The webinar will provide insights into the company's strategies for increasing direct-to-consumer, distributor, and retail sales [2][3].

Core Viewpoint - Quantum BioPharma Ltd. is seeking shareholder approval for a non-brokered private placement of class A multiple voting shares for gross proceeds of up to $600 million, with the meeting scheduled for September 26, 2025 [1][2]. Group 1: Offering Details - The entire offering is expected to be subscribed by existing holders of MVS and is anticipated to close on or about September 26, 2025, pending shareholder approval [2]. - Proceeds from the offering will be used for general working capital purposes [2]. - All securities issued will be subject to a statutory hold period of four months plus a day from issuance in accordance with Canadian securities laws [2]. Group 2: Company Overview - Quantum BioPharma is focused on developing innovative assets and biotech solutions for neurodegenerative and metabolic disorders, with drug candidates at various development stages [5]. - The company’s lead compound, Lucid-MS, is designed to prevent and reverse myelin degradation, a key factor in multiple sclerosis, and is currently in preclinical models [5]. - Quantum BioPharma retains a 20.11% ownership stake in Unbuzzd Wellness Inc., which includes a royalty agreement of 7% on sales until total payments reach $250 million, after which the royalty will drop to 3% [5].

Core Insights - Quantum BioPharma Ltd. has signed an agreement with a leading contract development and manufacturing organization (CDMO) to manufacture an oral drug formulation of Lucid-MS, which will be used in the upcoming Phase 2 clinical trial for multiple sclerosis (MS) [1][3] - Lucid-MS is a first-in-class, non-immunomodulatory, neuroprotective compound that has shown potential in preclinical models to prevent demyelination, a key characteristic of MS [2] - The company is preparing an Investigational New Drug (IND) application with the FDA as part of its clinical development strategy for Lucid-MS [3] Company Overview - Quantum BioPharma is focused on developing innovative therapies for neurodegenerative disorders and has a portfolio of drug candidates at various stages of development [4] - The company retains a 20.11% ownership stake in Unbuzzd Wellness Inc., which includes a royalty agreement of 7% on sales until total payments reach $250 million, after which the royalty will decrease to 3% [4] - Quantum BioPharma also maintains strategic investments through its subsidiary, FSD Strategic Investments Inc., which involves loans secured by residential or commercial property [4]

Core Insights - Quantum BioPharma Ltd. has signed an agreement with a leading contract development and manufacturing organization (CDMO) to manufacture an oral formulation of Lucid-MS, which will be used in the upcoming Phase 2 clinical trial for multiple sclerosis (MS) [1][3] - Lucid-MS is a first-in-class, non-immunomodulatory, neuroprotective compound that has shown potential in preclinical models to prevent demyelination, a key characteristic of MS [2][4] - The company is preparing an Investigational New Drug (IND) application with the FDA as part of its clinical development strategy for Lucid-MS [3] Company Overview - Quantum BioPharma is focused on developing innovative therapies for neurodegenerative disorders and metabolic disorders, with a portfolio that includes drug candidates at various stages of development [4] - The company retains a 20.11% ownership stake in Unbuzzd Wellness Inc., which is involved in the development of a product called unbuzzd™, and has a royalty agreement that includes 7% of sales until total payments reach $250 million, after which the royalty will drop to 3% [4] - Quantum BioPharma also maintains strategic investments through its subsidiary, FSD Strategic Investments Inc., which includes loans secured by residential or commercial property [4]